, Tracking Stock Market Picks
Enter Symbol:
Cytori Therapeutics Inc (CYTX) [hlAlert]

down 88.28 %

Cytori Therapeutics Inc (CYTX) rated Buy with price target $3.25 by Ascendiant Capital Markets

Posted on: Wednesday,  Feb 20, 2013  8:25 AM ET by Ascendiant Capital Markets

Ascendiant Capital Markets rated Buy Cytori Therapeutics Inc (NASDAQ: CYTX) on 02/20/2013, when the stock price was $2.56.
Since then, Cytori Therapeutics Inc has lost 88.28% as of 09/08/2015's recent price of $0.30.
If you would have followed this Ascendiant Capital Markets's recommendation on CYTX, you would have lost 88.28% of your investment in 930 days.

Cytori Therapeutics, Inc. develops, manufactures, and sells medical technologies to enable the practice of regenerative medicine. The Company?s commercial activities are focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, and stem and regenerative cell banking (cell preservation) in worldwide. Its product pipeline includes the development of new treatments for cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease and pelvic health conditions. The Company?s Celution System family of products processes patients? cells at the bedside in real time. During the year ended December 31, 2008, the Celution 800/CRS System was introduced into the European cosmetic and reconstructive surgery market through a network of medical distributors. The Celution 900/MB is marketed in Japan through its commercialization partner, Green Hospital Supply, Inc.

Ascendiant Capital Markets is led by George Santana, who has nearly twenty years of equity research experience in the United States and foreign markets. During his career, Mr. Santana has been recognized six consecutive times in the Institutional Investor magazine poll of top analysts.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/20/2013 8:25 AM Buy
2.56 3.25
as of 12/13/2013
1 Week down  -8.98 %
1 Month down  -4.89 %
3 Months down  -6.80 %
1 YTD down  -8.98 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy